Inozyme

Scroll
Investment area
Novo Ventures
Date of investment
January 2017

Inozyme Pharmaceuticals develops enzyme replacement therapies to treat orphan diseases characterized by aberrant calcification as a result of inorganic pyrophosphate (PPi) deficiency.